114870-03-0

• 常用中文名：磺达肝癸钠
• 常用英文名：Fondaparinux Sodium
• CAS号：114870-03-0
• 分子式：C₃₁H₅₃N₃Na₁₀O₄₉S₈
• 分子量：1738.16
• 相关类别： 生物化工 糖类化合物 寡糖
• 发布时间：2018-08-07 14:39:07
• 更新时间：2026-06-29 16:50:52
• Fondaparinux sodium 是一种抗凝血酶依赖性的 factor Xa 抑制剂。

名称

• 中文名: 磺达肝癸钠
• 英文名: fondaparinux sodium
• 中文别名: (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-羧基-4- 羟基-6-(((2R,3S,4R,5R,6S)-4-羟基-6-甲氧基-5-(磺氨基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基) 氧基)-5-(磺氧基)四氢-2H-吡喃-3-基)氧基)-5-(磺氨基)-4-(磺氧基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基 )氧基)-3-(((((2R,3R,4R,5S,6R)-4,5-二羟基-3-(磺氨基)-6-(((磺氧基)甲基)四氢-2H-吡喃-2-基)) 氧)-4,5-二羟基四氢-2H-吡喃-2-羧酸十钠盐; 化合物:Fondapinux (sodium salt); 磺达肝素(癸)钠; (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-羧基-4- 羟基-6-(((2R,3S,4R,5R,6S)-4-羟基-6-甲氧基-5-(磺氨基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基) 氧基)-5-(磺氧基)四氢-2H-吡喃-3-基)氧基)-5-(磺氨基)-4-(磺氧基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基 )氧基)-3-(((((2R,3R,4R,5S,6R)-4,5-二羟基-3-(磺氨基)-6-(((磺; FONDAPINUX SODIUM 磺达肝癸钠; 磺达肝素钠鉴定; 磺达肝葵纳; Fondapinux Sodium :磺达肝癸钠; 磺达肝素钠; (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-羧基-4- 羟基-6-(((2R,3S,4R,5R,6S)-4-羟基-6-甲氧基-5-(磺氨基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基) 氧基)-5-(磺氧基)四氢-2H-吡喃-3-基)氧基)-5-(磺氨基)-4-(磺氧基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基 )氧基)-3-(((((2R,3R,4R,5S,6R)-4,5-二羟基-3-(磺氨基)-6-(((磺氧基)甲基)四氢-2H-吡喃-2-基)) 氧)-4,5-二羟基四氢-2H-吡喃-2-羧; 磺达肝素钠盐; FACTOR XA抑制剂(FONDAPINUX SODIUM); 磺达肝素钠(磺达肝癸钠); (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-羧基-4- 羟基-6-(((2R,3S,4R,5R,6S)-4-羟基-6-甲氧基-5-(磺氨基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基) 氧基)-5-(磺氧基)四氢-2H-吡喃-3-基)氧基)-5-(磺氨基)-4-(磺氧基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基 )氧基)-3-(((((2R,3R,4R,5S,6R)-4,5-二羟基-3-(磺氨基)-6; Fondapinux Sodium 磺达肝癸钠,S3736; 戊聚糖钠; 黄达肝葵钠; 磺达甘癸钠; 化合物：Fondapinux (sodium salt); 磺达肝葵钠杂质2; Fondapinux Sodium 磺达肝癸钠，S3736; 磺达肝癸钠 FONDAPINUX SODIUM; (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-羧基-4- 羟基-6-(((2R,3S,4R,5R,6S)-4-羟基-6-甲氧基-5-(磺氨基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基) 氧基)-5-(磺氧基)四氢-2H-吡喃-3-基)氧基)-5-(磺氨基)-4-(磺氧基)-2-(((磺氧基)甲基)四氢-2H-吡喃-3-基 )氧基)-3-(((((2R,3R,4R,5S,6R)-4,5-二羟基-3-(磺氨基)-6-(((磺氧基)甲基)四氢-2H-吡喃-2-基)) 氧)-4,5-二羟基四氢-2H-吡喃-2-羧酸十
• 英文别名: Sodium dapinux; Fondapinux sodium //BP; Decasodium methyl 2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-β-D-glucopyranuronosyl-(1->4)-2-deoxy-3,6-di-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-2- O-sulfonato-α-L-idopyranuronosyl-(1->;4)-2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranoside; a-D-Glucopyranoside, methylO-2-deoxy-6-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(14)-O-b-D-glucopyranuronosyl-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-O-2-O-sulfo-a-L-idopyranuronosyl-2-deoxy-2-(sulfoamino)-,6-(hydrog; Fondapinux sodium, >=; ixtra (tn); Fondaparin sodium; Fondaparinux sodium; Fondapinux Sodium for Assay (COLD SHIPMENT REQUIRED); Fondapinux Sodium Identification(Secondy Standds traceble to; Methyl O-2-Deoxy-6-O-sulfo-2-(sulfoaMino)-α-D-glucopyranosyl-(14)-O-β- D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoaMino)-α-D-glucopyranosyl-O-2-O-sulfo-α-L-idopyranuronosyl-2-deoxy-2-(sulfoaMino)-α-D-glucopyranoside 6-(Hydrogen Sulfate) DecasodiuM Salt; decasodium (2R,3S,4S,5R,6R)-3-[(2R,3R,4R,6R)-5-[(2R,3R,4S,5S,6S)-6-cboxylato-5-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-oxan-2-yl]oxy-3-(sulfonatoamino)-4-sulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxy-oxane-2-cboxylate; (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-Cboxy-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfoamino)-4-(sulfooxy)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-(((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-((sulfooxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-2-cboxylic acid, decasodium salt; Fondapinux SodiuM Identification; Fondapinux sodium (jan/usan/inn); α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10); D01844; Natural hin pentasacchide Sodium; Fondapinux (sodium salt); Arixtra; Methyl O-2-Deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-β- D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-O-2-O-sulfo-α-L-idopyranuronosyl-2-deoxy-2-(sulfoamino)-α-D-glucopyra; decasodium 6-[[6-[[2-cboxylato-4-hydroxy-6-[[4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)-3-oxanyl]oxy]-5-sulfonatooxy-3-oxanyl]oxy]-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatoox; (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-cboxy-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfoamino)-4-(sulfooxy)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-(((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-((sulfooxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-2-cboxylic acid, sodium salt; US-DMF No.; ixtra; Fondapinux and intermediates; Fondapin SodiuM; α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), decasodium salt; Fondaparinux (sodium); decasodium 6-[[6-[[2-cboxylato-4-hydroxy-6-[[4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)-3-oxanyl]oxy; Fondapinux sodium N-4; Fondapinux sodiuM(D01844); Fondapinux sodium; (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-Cboxy-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfoamino)-4-(sulfooxy); Fondapinux Sodium (Fondapinux Sodium); Fondapinux Sodiun; decasodiuM (2R,3S,4S,5R,6R)-3-{[(2R,3R,4R,5R,6R)-5-{[(2R,3R,4R,5S,6S)-6-cboxylato-5-{[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoaMino)-6-[(sulfonatooxy)Methyl]oxan-2-yl]oxy}-3,4-dihydroxyoxan-2-yl]oxy}-3-(sulfonatoaMino)-4-(sulfonatooxy)-6-[(sulfonatoo; α-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4 )-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10)

物化性质

• 分子式: C₃₁H₅₃N₃Na₁₀O₄₉S₈
• 分子量: 1738.16
• PSA: 900.82000
• 储存条件: -20°C，惰性气体存储

生物活性

• 描述: Fondaparinux sodium 是一种抗凝血酶依赖性的 factor Xa 抑制剂。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 因子Xa
  研究领域 >> 心血管疾病
• 靶点:

  Factor Xa[1]

• 体外研究: 磺达肝素钠是第一种选择性靶向Xa因子的新型抗凝血剂。对于磺达肝素,其活化单核细胞(ac-M)的IC50值(抗-Xa IU/ml)为0.59±0.05,单核细胞衍生的微粒(MMP)为0.17±0.03 [2]。
• 体内研究: 磺达肝素钠具有线性,剂量依赖性药代动力学特征,其提供高度可预测的响应。磺达肝素钠具有100％生物利用度,起效迅速,半衰期为14至16小时,可在24小时内持续抗血栓形成。该药物不影响凝血酶原时间或活化部分促凝血酶原激酶时间,也不影响血小板功能或聚集[1]。
• 参考文献:

  [1]. Bauer KA. et al. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7.

  [2]. Ben-Hadj-Khalifa S, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011 Jul;22(5):369-73.

安全

• 危险品运输编码: NONH for all modes of transport